| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w24026 |
| 来源ID | Working Paper 24026 |
| Characterizing the Drug Development Pipeline for Precision Medicines | |
| Amitabh Chandra; Craig Garthwaite; Ariel Dora Stern | |
| 发表日期 | 2017-11-20 |
| 出版年 | 2017 |
| 语种 | 英语 |
| 摘要 | Precision medicines – therapies that rely on the use of genetic, epigenetic, and protein biomarkers – create a better match between patients with specific disease subtypes and medications that are more effective for those patients. This heterogeneity in response has implications for the decision to develop therapies, their pricing, the design of clinical trials, and the relative importance of smaller biotech companies versus more traditional companies in pursuing early stage R&D. To understand the scope of these effects, we use a comprehensive database of over 130,000 global clinical trials and describe the drug development pipeline for precision medicines over the past two decades. We identify clinical trials for likely precision medicines (LPMs) as those that use one or more relevant biomarkers. We then further segment trials based on the nature of the biomarker(s) used and other trial features with economic implications. Since cancers represent a disease setting in which precision therapies are already successfully used, and since cancer applications of precision medicine are expected to grow rapidly over the coming years, we separately characterize cancer LPMs. Finally, we consider the types of firms pursuing R&D in precision medicines, considering how LPM R&D activities have evolved over recent years. |
| 主题 | Health, Education, and Welfare ; Health ; Industrial Organization ; Regulatory Economics ; Development and Growth ; Innovation and R& ; D |
| URL | https://www.nber.org/papers/w24026 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/581700 |
| 推荐引用方式 GB/T 7714 | Amitabh Chandra,Craig Garthwaite,Ariel Dora Stern. Characterizing the Drug Development Pipeline for Precision Medicines. 2017. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w24026.pdf（947KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
